Clinical trial
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00090987 · AIDS Malignancy Consortium, Other · Completed
Key facts
| NCT number | NCT00090987 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma |
| Official title | A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma |
| Lead sponsor | AIDS Malignancy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH The Emmes Company, LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 30 |
| Start date | Jun 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 8, 2004 |
| Last update posted | Jun 6, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: